Catalyst MedTech Launches "Connect" Program to Expand Access to Advanced Imaging; Announces Initial Partnership with Algernon Pharmaceuticals

PITTSBURGH, Oct. 7, 2025 /PRNewswire/ -- Catalyst MedTech today announced the launch of its new Connect program, an initiative that brings together collaborators seeking to advance patient care with the access required to make it possible. Connect leverages Catalyst's unique dual business structure—Equipment Solutions and Clinical Solutions—to deliver customizable pathways that expand access to diagnostic imaging and treatment. Connect ensures innovation has a pathway to reach the patients it was built for.

As part of the launch, Catalyst also announced its first Connect partnership with Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian publicly traded healthcare company, focused on expanding access to Optimized Brain PET imaging in the United States. By enrolling as a Connect Partner, Algernon is moving forward with its plan to establish the first dedicated network of neuroimaging medical clinics in the United States for the early-stage detection of Alzheimer's. Catalyst is powering this vision with a tailored mix of equipment, service, and support—featuring the Optimized Brain PET solution that combines CareMiBrain™ with the NeuroQ® advanced quantitative workstation.

"The vision of Connect is to help finish the story for our partners," said Martin B Shirley, CEO & President of Catalyst MedTech.  "Many companies want to make an impact in a specific space — whether in neurology, cardiology, or beyond. Catalyst is the connector that makes those ambitions real by providing the access, expertise, and solutions needed to bridge vision and execution. We connect the dots directly to the patients for their benefit."

With millions at risk for Alzheimer's and related conditions, dedicated Brain PET is increasingly recognized as the standard for earlier, more confident diagnosis. The optimized CareMiBrain™ system, exclusively distributed in the U.S. by Catalyst MedTech sets a new benchmark in neurologic imaging. The complete system combines ultra-high resolution imaging within a compact, patient-friendly design with an advanced quantitative neurologic workstation — delivering diagnostic precision and practical scalability for neurology practices, imaging centers, and hospitals.

"We are very excited to be working with Catalyst MedTech to accelerate access to Brain PET in the U.S.," said Christopher J. Moreau, CEO of Algernon Pharmaceuticals Inc. "Catalyst's ability to connect the dots between innovation, access, and patient care perfectly aligns with our mission to establish a network of advanced neuroimaging clinics. Together, we can make a meaningful difference in how patients with Alzheimer's and other neurodegenerative conditions are diagnosed and treated."

Catalyst MedTech continues to position itself as the thought leader and connector in advanced imaging. By creating pathways for adoption, Catalyst MedTech ensures that breakthroughs in imaging translate into better care, earlier answers, and improved patient outcomes.

About Catalyst MedTech
Catalyst MedTech is a nationwide provider of nuclear medicine, molecular imaging, and CT solutions. Our purpose is simple but powerful: to deliver value and access through advanced diagnostic imaging and related therapies—so patients get the care and treatments they need.

With OEM-trained service teams, clinical expertise, and a multi-vendor equipment portfolio, we support providers in cardiology, neurology, and beyond. As an OEM that is also the largest NM/MI independent ISO-certified service provider in the U.S., Catalyst MedTech is helping healthcare organizations achieve earlier answers, stronger confidence, and better outcomes—seeing what's possible in diagnostic imaging today and tomorrow.

Visit www.catalystmedtech.com for more information.

Media Contact: Kate Kinsell, [email protected]m

About Algernon Pharmaceuticals

Algernon Pharmaceuticals (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) is a Canadian healthcare company focused on the provision of brain specific PET scanning services through a planned network of new clinics in North America for the early-stage detection of Alzheimer's disease, as well as other forms of dementia, epilepsy, neuro-oncology, and movement disorders. Algernon is also the parent company of a private subsidiary called Algernon NeuroScience that has been advancing a psychedelic program investigating a proprietary form of DMT for stroke and traumatic brain injury. The Company also owns a 20% equity position in Seyltx, a private U.S. based drug development company advancing a chronic cough drug called Ifenprodil.

Visit www.algernonpharmaceuticals.com for more information.

SOURCE Catalyst MedTech